Osteoporosis Drugs May Slow Aortic Aneurysm Progression

Researchers at Nagoya University in Japan have identified a potential non-surgical approach to treating aortic aneurysms, finding that commonly used osteoporosis drugs may slow or halt the progression of the disease. The findings, published in the Journal of Clinical Investigation, suggest a new therapeutic pathway for a condition that currently lacks effective drug therapies to stop its advancement.

Aortic aneurysms are characterized by the abnormal enlargement of the aorta, which is the primary artery responsible for carrying blood from the heart. Because a rupture of the aorta often leads to sudden death, the ability to slow the enlargement of the vessel is critical for reducing mortality.

The Role of Clonal Hematopoiesis

The research team, led by Assistant Professor Yoshimitsu Yura and graduate student Jun Yonekawa of the Nagoya University Graduate School of Medicine, investigated the association between aortic aneurysms and clonal hematopoiesis. Clonal hematopoiesis is an age-related process in which blood-forming stem cells acquire genetic mutations.

While clonal hematopoiesis has been recognized as a contributor to other age-related conditions, including osteoporosis and various cardiovascular diseases, its specific link to aortic aneurysms had previously remained unclear. The Nagoya University study found that this process accelerates the progression of the aneurysm.

The researchers hypothesized that macrophages derived from clonal hematopoiesis are the primary drivers of this acceleration. The study identified a key mechanism by which these macrophages contribute to the degradation of the extracellular matrix, which weakens the aortic wall and allows it to enlarge.

Repurposing Osteoporosis Medications

By understanding the underlying mechanism of matrix degradation, the researchers explored the use of existing medications. The study demonstrated that osteoporosis drugs, which are designed to maintain bone density and structural integrity, could be repurposed to treat the aorta.

In tests conducted on mice, the researchers showed that these osteoporosis drugs slowed the progression of the disease. This suggests that the drugs may interfere with the destructive processes led by mutated macrophages, providing a potential pharmacological alternative to invasive procedures.

Current Treatment Limitations

As of April 14, 2026, surgery remains the only definitive treatment for aortic aneurysms. Because there are no approved drug therapies to halt the enlargement of the aorta, medical professionals must rely on surgical intervention to prevent rupture.

Surgical decisions are currently guided by the assessed risk of rupture, which is determined through imaging. Clinicians evaluate several factors to decide when to operate, including:

• The diameter of the aneurysm
• Morphological features of the vessel
• The rate of expansion

Despite these imaging tools, it remains difficult for physicians to predict which specific patients will experience progressive enlargement. The research from Nagoya University highlights the need for additional indicators to better stratify the risk of disease progression among patients.

The discovery of the link between clonal hematopoiesis and aneurysm progression may provide these necessary indicators while offering a new method to manage the disease without immediate recourse to surgery.